Effect of miR-548j-5p expression on invasion of pancreatic cancer

doi:10.3877/cma.j.issn.2095-3232.2018.01.020

Abstract

Abstract:

Objective

To explore the expression of miR-548j-5p in pancreatic cancer and its effect on the invasion of pancreatic cancer.

Methods

Tissue samples of 16 patients with pancreatic cancer who received treatment in Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology between January 2016 and January 2017 were collected. There were 8 males and 8 females, aged from 41 to 62, including 7 cases with an age of ≤50 and 9 cases with an age of >50. The informed consents of all patients were obtained and the local ethical committee approval was received. The expression of miR-548j-5p in pancreatic cancer and adjacent tissues was detected by RT-PCR. PANC-1 cells were transfected by mimic and inhibitor of miR-548j-5p to construct PANC-1 cells with over-expression and low-expression of miR-548j-5p. And in control group, PANC-1 cells were transfected with empty plasmid Ctrl. The effect of miR-548j-5p on PANC-1 invasion was detected by Transwell assay, and its effect on PANC-1 metastasis was evaluated by wound scratch assay. Comparison of three groups was conducted by one-way analysis of variance and LSD-t test.

Results

The median relative expression of miR-548j-5p in pancreatic cancer was 0.35(0.03-4.47), significantly lower than 4.30 (0.04-65.55) in adjacent tissues (Z=-2.689, P<0.05). Transwell assay results showed that the average number of cells penetrating membrane was (58±34) in miR-548j-5p over-expression group, significantly lower than (231±61) in control group (LSD-t=-2.852, P<0.05); and it was (491±149) in miR-548j-5p low-expression group, significantly higher than that in control group (LSD-t=4.313, P<0.05). The wound scratch assay results showed that the wound scratch healing rate was (20±8)% in miR-548j-5p over-expression group, significantly lower than (38±6)% in control group (LSD-t=-3.759, P<0.05); and it was (53±6)% in miR-548j-5p low-expression group, significantly higher than that in control group (LSD-t=2.946, P<0.05).

Conclusions

Low expression of miR-548j-5p is observed in pancreatic cancer. Over expression of miR-548j-5p can decrease the invasive and metastatic ability of pancreatic cancer.

Key words: MicroRNAs, Pancreatic neoplasms, Neoplasm invasiveness, Neoplasm metastasis, 548j-5p gene

Ruizhi He, Feng Peng, Yechen Feng, Xingjun Guo, Xu Li, Min Wang, Rui Tian, Feng Zhu, Renyi Qin. Effect of miR-548j-5p expression on invasion of pancreatic cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2018, 07(01): 82-86.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2018.01.020

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2018/V07/I01/82

Figures/Tables 3

References 21

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
[2]	Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 155(6):977-988.
[3]	Genovese G, Carugo A, Tepper J, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer[J]. Nature, 2017, 542(7641):362-366.
[4]	Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy[J]. Expert Opin Ther Targets, 2016, 20(3):341-359.
[5]	Adams BD, Parsons C, Walker L, et al. Targeting noncoding RNAs in disease[J]. J Clin Invest, 2017, 127(3):761-771.
[6]	Yonemori K, Kurahara H, Maemura K, et al. MicroRNA in pancreatic cancer[J]. J Hum Genet, 2017, 62(1):33-40.
[7]	Huang J, Liu J, Chen-Xiao K, et al. Advance in microRNA asa potential biomarker for early detection of pancreatic cancer[J]. Biomark Res, 2016(4):20.
[8]	Merhautova J, Demlova R, Slaby O. MicroRNA-based therapy in animal models of selected gastrointestinal cancers[J]. Front Pharmacol, 2016(7):329.
[9]	Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker[J]. Clin Cancer Res, 2017, 23(1):116-123.
[10]	Zoghbi HY, Beaudet AL. Epigenetics and human disease[J]. Cold Spring Harb Perspect Biol, 2016, 8(2):a019497
[11]	Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy[J]. Cancer Treat Rev, 2017(55):200-208.
[12]	Biswas S, Rao CM. Epigenetics in cancer: fundamentals and beyond[J]. Pharmacol Ther, 2017(173):118-134.
[13]	van Kampen JG, Marijnissen-van Zanten MA, Simmer F, et al. Epigenetic targeting in pancreatic cancer[J]. Cancer Treat Rev, 2014, 40(5):656-664.
[14]	Frampton AE, Castellano L, Colombo T, et al. Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression[J]. Lancet, 2015, 385 Suppl 1:S37.
[15]	Wang C, Liu P, Wu H, et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3[J]. Oncotarget, 2016, 7(12):14912-14924.
[16]	Botla SK, Savant S, Jandaghi P, et al. Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression[J]. Cancer Res, 2016, 76(14):4149-4159.
[17]	Piriyapongsa J, Jordan IK. A family of human microRNA genes from miniature inverted-repeat transposable elements[J]. PLoS One, 2007, 2(2):e203.
[18]	Shi Y, Qiu M, Wu Y, et al. MiR-548-3p functions as an anti-oncogenic regulator in breast cancer[J]. Biomed Pharmacother, 2015(75):111-116.
[19]	Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3):203-222.
[20]	Li Y, Xie J, Xu X, et al. MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1[J]. Protein Cell, 2013, 4(2):130-141.
[21]	Zhan Y, Liang X, Li L, et al. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1[J]. Mol Oncol, 2016, 10(6):838-849.

Please choose a citation manager

Content to export